Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.

The aromatic fatty acid sodium phenylbutyrate (PB) promotes cytostasis and differentiation in a wide variety of tumor types; among several molecular activities, inhibition of histone deacetylase (HDAC) may account for many of its pharmacodynamic effects. A Phase I study demonstrated promising preliminary evidence of clinical activity in acute myeloid leukemia and myelodysplastic syndrome; however, plasma concentrations achieved at the maximum tolerated dose were less than those targeted based on in vitro studies. Because prolonged exposure to suboptimal concentrations of PB in vitro led to pharmacodynamic changes similar to a more brief exposure to higher concentrations, a study of the feasibility of prolonged administration of sodium PB was performed. Selected patients with acute myeloid leukemia and myelodysplastic syndrome were treated with sodium PB as a continuous i.v. infusion via ambulatory infusion pump. Sequential cohorts were treated for 7 consecutive days out of 14 or with 21 consecutive days out of 28. Prolonged infusions were well tolerated; dose-limiting central nervous system toxicity developed in 1 of 23 patients treated. End-of-infusion plasma concentrations were maintained within a range sufficient to inhibit HDAC. Two patients on the 21/28 schedule developed hematological improvement. Prolonged infusions of PB are well tolerated making this an attractive platform for the clinical investigation of HDAC inhibition.

[1]  M. Grever,et al.  Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  M. Carducci,et al.  Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors , 2000, Expert opinion on investigational drugs.

[3]  D. Dean,et al.  Chromatin remodeling and transcriptional regulation. , 1999, Journal of the National Cancer Institute.

[4]  S. Piantadosi,et al.  Augmentation of phenylbutyrate-induced differentiation of myeloid leukemia cells using all-trans retinoic acid , 1999, Leukemia.

[5]  D. Samid,et al.  Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: structure–function analysis , 1999, Leukemia.

[6]  Johnson M Liu,et al.  Chromatin remodeling and leukemia: new therapeutic paradigms. , 1999, Blood.

[7]  J. Herman,et al.  Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer , 1999, Nature Genetics.

[8]  A. Sartorelli,et al.  Coinduction of embryonic and adult-type globin mRNAs by sodium butyrate and trichostatin A in two murine interleukin-3-dependent bone marrow-derived cell lines. , 1998, Blood.

[9]  P. Pandolfi,et al.  Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. , 1998, Journal of the National Cancer Institute.

[10]  Colin A. Johnson,et al.  Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex , 1998, Nature.

[11]  S. Inoue,et al.  Role of the histone deacetylase complex in acute promyelocytic leukaemia , 1998, Nature.

[12]  D. Samid,et al.  Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  D. Samid,et al.  Disposition of Phenylbutyrate and its Metabolites, Phenylacetate and Phenylacetylglutamine , 1995, Journal of clinical pharmacology.

[14]  S. Brusilow,et al.  Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. , 1994, Blood.

[15]  C. Schiffer,et al.  Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. , 1993, Leukemia.

[16]  E. Dmitrovsky,et al.  Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). , 1991, The New England journal of medicine.

[17]  Y. Kan,et al.  Stopping the Biologic Clock for Globin Gene Switching a , 1990, Annals of the New York Academy of Sciences.

[18]  R. He,et al.  Combinations of retinoic acid with either sodium butyrate, dimethyl sulfoxide, or hexamethylene bisacetamide synergistically induce differentiation of the human myeloid leukemia cell line HL60. , 1990, Cancer research.

[19]  M R Loken,et al.  Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development. , 1987, Blood.